Truist Securities analyst Barry Jonas downgrades Red Rock Resorts (NASDAQ:RRR) from Buy to Hold.
Credit Suisse Maintains Outperform on Prometheus Biosciences, Raises Price Target to $59
Credit Suisse analyst Tiago Fauth maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $52 to $59.